As you will understand Rituxan (rituximab) could be a new generation cancer drug that in clinical follow proved a lot of precise and less toxic than previous chemotherapy compounds that are used to fight cancer. Really, it's a completely completely different sort of drug then the chemotherapeutic agents. All chemotherapy drugs are chemical compounds. Rituxan on the opposite hand could be a protein and it is also an antibody.
Antibodies are basic protein agents of our body immune defense system. Antibodies have an exquisite feature of recognizing specific antigens, which is any foreign substance that provokes the immune response when introduced into the body. Antigens most often are proteins and polysaccharides, but can be any type of molecule. Each antibody recognizes solely a particular single antigen. That is why antibody therapies may be terribly precise, inactivating just one issue that would possibly be the culprit of a disease. Chemotherapeutic agents on the other hand interfere with numerous normal body functions. There is a promise of antibody therapies to offer very precise and powerful weapons to fight simply the disease and to not interfere with the normal, healthy cells and body activities. Rituxan supposed to be one in every of them and it's already clinically proven to be of a great therapeutic value. Rituxan antibody is directed against the CD20 antigen found on the surface of traditional and malignant B lymphocytes (kind of white blood cells). In medical conditions where B lymphocytes are the disease issue Rituxan ought to facilitate to destroy the diseased B lymphocytes. The vital fact is that the CD20 antigen isn't found on hematopoietic stem cells and on pro-B cells [1], that provide rise to new populations of mature B lymphocytes in a constant renewal method in our body. This manner the idea of Rituxan therapy is to urge rid of the diseased mature B lymphocytes and to allow the body to provide new healthy ones from its own resources.
Rituxan is already approved to treat a blood cancer referred to as lymphoma and rheumatoid arthritis and tests in other immune diseases (as well as lupus and multiple sclerosis among others) are underway. Rituxan is likely to find broad markets well beyond cancer treatment, as the B-lymphocytes would possibly be factors in different diseases too. Such prospect might cause multibillion-dollar sales. That usually translates into terribly aggressive advertising campaigns, and in turn it influences treatment and prescription decisions made by health professionals. With larger patient populations in treatment even infrequent adverse reactions come back into play on a significant scale. Additionally, once a medication has been approved for promoting for a bound use, experience could show that it is additionally helpful for different medical problems. Though these uses aren't included in product labeling, Rituxan is utilized in bound patients with alternative medical conditions in so called off-label applications. One in all such treatment is in a very disease known as systemic lupus erythematosus, that may be a form of lupus, a condition of chronic inflammation caused by an autoimmune disease. This is often where recently worrisome reports emerged concerning patients treated with Rituxan.
On December eighteenth 2006 US Food and Drug Administration issued a warning highlighting vital emerging safety information regarding Rituxan. 2 patients have died once being treated with Rituxan for systemic lupus erythematosus. The cause of death was a viral infection of the brain called progressive multifocal leukoencephalopathy (PML). PML is caused by the reactivation of a common virus, called the JC virus, in the central nervous system (brain and therefore the spinal cord) of immune-compromised individuals. The JC virus (JCV) is very common within the human population, with the estimation of seventy to 90 percent folks acquiring JCV in childhood or adolescence [2], and is carried by a majority of people in thus referred to as latent type, that means it's dormant and is harmless except among those with lowered immune defenses most frequently by a disease or immunosuppressive therapy. There is no specific antiviral therapy that has been proven effective for JCV, and patients who have PML sometimes deteriorate rapidly and death commonly happens at intervals 6 months of diagnosis [3].
The FDA safety warning when the death of two patients treated with Rituxan and extra 23 cases reported by FDA of rheumatoid arthritis and lymphoma patients, who have contracted the brain illness while or shortly after being treated with Rituxan, sends a terribly sturdy message to patients and physicians, concerning the Rituxan therapy. It will be vital to observe such cases and to achieve a higher understanding of Rituxan unfavorable aspect effects, since the reactivation or exacerbation of viral infections as well as JC virus resulting in PML might occur when patients receive Rituxan for any reason.
To decide to use a medicine, the risks of taking the drugs must be weighed against the good it can do. This can be a decision you and your doctor should make. In the sunshine of the FDA warning, patients who are treated with Rituxan and present or develop new neurological signs or symptoms ought to be evaluated for PML. It's your health and you have to act wise. In the end it would possibly not be very appealing to become a client of a Law Workplace in Rituxan lawsuit of injured Rituxan patient. As "money makes the world go round" there are already law offices advertising services in Rituxan lawsuit. Nevertheless, you'll be able to be certain, your health is value additional than any probably won lawsuit.
Author Resource:-
Coye Daniels has been writing articles online for nearly 2 years now. Not only does this author specialize in diseases,you can also check out his latest website about:
Duns Number Lookup Which reviews and lists the best
![[Valid RSS feed]](http://www.fyifiles.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites
